Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -88.9% | -17.9% | -69.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -1,042.5% | 33.8% | -4,926.7% | 62.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -165,724% | -12,178.9% | -5,890.4% | -1,074.6% |
| Other Income/Exp. Net | $2 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $2 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $2 | -$0 | -$0 | -$0 |
| % Margin | 843,786% | -13,408.9% | -6,625.3% | -1,147.6% |
| EPS | 116.58 | -5.12 | -3.62 | -2.15 |
| % Growth | 2,377% | -41.4% | -68.4% | – |
| EPS Diluted | 116.58 | -5.12 | -3.62 | -2.15 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $2 | -$0 | -$0 | -$0 |
| % Margin | 851,675% | -11,482.9% | -5,739.8% | -1,057.8% |